Head & Neck Institute, Cleveland, Ohio, USA.
Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Otolaryngol Head Neck Surg. 2021 Apr;164(2_suppl):S1-S42. doi: 10.1177/0194599821996297.
Opioid use disorder (OUD), which includes the morbidity of dependence and mortality of overdose, has reached epidemic proportions in the United States. Overprescription of opioids can lead to chronic use and misuse, and unused narcotics after surgery can lead to their diversion. Research supports that most patients do not take all the prescribed opioids after surgery and that surgeons are the second largest prescribers of opioids in the United States. The introduction of opioids in those with OUD often begins with prescription opioids. Reducing the number of extra opioids available after surgery through smaller prescriptions, safe storage, and disposal should reduce the risk of opioid use disorder in otolaryngology patients and their families.
The purpose of this specialty-specific guideline is to identify quality improvement opportunities in postoperative pain management of common otolaryngologic surgical procedures. These opportunities are communicated through clear actionable statements with explanation of the support in the literature, evaluation of the quality of the evidence, and recommendations on implementation. Employing these action statements should reduce the variation in care across the specialty and improve postoperative pain control while reducing risk of OUD. The target patients for the guideline are any patients treated for anticipated or reported pain within the first 30 days after undergoing common otolaryngologic procedures. The target audience of the guideline is otolaryngologists who perform surgery and clinicians who manage pain after surgical procedures. Outcomes to be considered include whether the patient has stopped using opioids, has disposed of unused opioids, and was satisfied with the pain management plan.The guideline addresses assessment of the patient for OUD risk factors, counseling on pain expectations, and identifying factors that can affect pain duration and/or severity. It also discusses the use of multimodal analgesia as first-line treatment and the responsible use of opioids. Last, safe disposal of unused opioids is discussed.This guideline is intended to focus on evidence-based quality improvement opportunities judged most important by the guideline development group. It is not a comprehensive guide on pain management in otolaryngologic procedures. The statements in this guideline are not intended to limit or restrict care provided by clinicians based on their experiences and assessments of individual patients.
The guideline development group made for the following key action statements: (3A) prior to surgery, clinicians should identify risk factors for opioid use disorder when analgesia using opioids is anticipated; (6) clinicians should advocate for nonopioid medications as first-line management of pain after otolaryngologic surgery; (9) clinicians should recommend that patients (or their caregivers) store prescribed opioids securely and dispose of unused opioids through take-back programs or another accepted method.The guideline development group made for the following key action statements: (1) prior to surgery, clinicians should advise patients and others involved in the postoperative care about the expected duration and severity of pain; (2) prior to surgery, clinicians should gather information specific to the patient that modifies severity and/or duration of pain; (3B) in patients at risk for OUD, clinicians should evaluate the need to modify the analgesia plan; (4) clinicians should promote shared decision making by informing patients of the benefits and risks of postoperative pain treatments that include nonopioid analgesics, opioid analgesics, and nonpharmacologic interventions; (5) clinicians should develop a multimodal treatment plan for managing postoperative pain; (7) when treating postoperative pain with opioids, clinicians should limit therapy to the lowest effective dose and the shortest duration; (8A) clinicians should instruct patients and caregivers how to communicate if pain is not controlled or if medication side effects occur; (8B) clinicians should educate patients to stop opioids when pain is controlled with nonopioids and stop all analgesics when pain has resolved; (10) clinicians should inquire, within 30 days of surgery, whether the patient has stopped using opioids, has disposed of unused opioids, and was satisfied with the pain management plan.
阿片类药物使用障碍(OUD)包括依赖的发病率和过量的死亡率,在美国已达到流行程度。阿片类药物的过度处方可导致慢性使用和滥用,手术后未使用的麻醉性镇痛药可能会导致其被转移用途。研究支持大多数患者在手术后不会服用所有规定的阿片类药物,而且外科医生是美国第二大阿片类药物处方开具者。在 OUD 患者中引入阿片类药物通常始于处方阿片类药物。通过较小的处方、安全储存和处置来减少手术后可用的额外阿片类药物数量,应降低耳鼻喉科患者及其家属发生阿片类药物使用障碍的风险。
本专业特定指南旨在确定常见耳鼻喉科手术术后疼痛管理中质量改进的机会。这些机会通过明确的可操作语句传达,同时解释文献中的支持、对证据质量的评估以及对实施的建议。采用这些行动性陈述应减少整个专业领域内护理的差异,并改善术后疼痛控制,同时降低 OUD 风险。本指南的目标患者是在接受常见耳鼻喉科手术后 30 天内接受预期或报告疼痛治疗的任何患者。本指南的目标受众是进行手术的耳鼻喉科医生和管理手术后疼痛的临床医生。要考虑的结果包括患者是否已停止使用阿片类药物、是否已处理未使用的阿片类药物以及对疼痛管理计划是否满意。该指南涉及评估患者是否存在 OUD 风险因素、关于疼痛预期的咨询以及确定可能影响疼痛持续时间和/或严重程度的因素。它还讨论了使用多模式镇痛作为一线治疗和合理使用阿片类药物。最后,讨论了未使用的阿片类药物的安全处置。本指南旨在重点关注指南制定小组认为最重要的基于证据的质量改进机会。它不是耳鼻喉科手术疼痛管理的综合指南。本指南中的陈述并不旨在限制或限制临床医生根据其经验和对个体患者的评估来提供的护理。
指南制定小组提出了以下关键行动声明:(3A)在需要使用阿片类药物镇痛时,临床医生应在手术前识别出阿片类药物使用障碍的风险因素;(6)临床医生应提倡将非阿片类药物作为耳鼻喉科手术后疼痛管理的一线治疗方法;(9)临床医生应建议患者(或其护理人员)安全储存规定的阿片类药物,并通过药品回收计划或其他可接受的方法处置未使用的阿片类药物。指南制定小组提出了以下关键行动声明:(1)在手术前,临床医生应告知患者和参与术后护理的人员有关疼痛预期的持续时间和严重程度的信息;(2)在手术前,临床医生应收集特定于患者的信息,以修改疼痛的严重程度和/或持续时间;(3B)对于存在 OUD 风险的患者,临床医生应评估是否需要修改镇痛方案;(4)临床医生应通过告知患者包括非阿片类镇痛药、阿片类镇痛药和非药物干预在内的术后疼痛治疗的益处和风险,促进共同决策;(5)临床医生应制定多模式治疗计划来管理术后疼痛;(7)在使用阿片类药物治疗术后疼痛时,临床医生应将治疗限制在最低有效剂量和最短持续时间;(8A)临床医生应指导患者和护理人员如果疼痛未得到控制或出现药物副作用时应如何沟通;(8B)临床医生应教育患者在疼痛得到非阿片类药物控制时停止使用阿片类药物,并在疼痛缓解时停止所有镇痛药物;(10)临床医生应在手术后 30 天内询问患者是否已停止使用阿片类药物、是否已处理未使用的阿片类药物以及对疼痛管理计划是否满意。